NRXS Neuraxis, INC

NYSE www.neuraxis.com


$ 2.40 $ 0.02 (0.79 %)    

Monday, 10-Nov-2025 18:20:15 EST
QQQ $ 620.48 $ 0.00 (0 %)
DIA $ 473.92 $ 0.00 (0 %)
SPY $ 679.76 $ 0.00 (0 %)
TLT $ 89.45 $ 0.00 (0 %)
GLD $ 380.37 $ 0.00 (0 %)
$ 2.56
$ 2.66
$ 2.40 x 30
$ 2.60 x 90
-- - --
$ 1.33 - $ 6.20
48,209
na
27.27M
$ 1.39
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-10-2025 09-30-2025 10-Q
2 08-12-2025 06-30-2025 10-Q
3 05-12-2025 03-31-2025 10-Q
4 03-20-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-09-2024 06-30-2024 10-Q
7 05-20-2024 03-31-2024 10-Q
8 04-16-2024 12-31-2023 10-K
9 11-20-2023 09-30-2023 10-Q
10 09-22-2023 06-30-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 neuraxis-q3-eps-024-misses-017-estimate-sales-811414k-miss-1000m-estimate

Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.17) by 4...

 neuraxis-earnings-preview
Neuraxis Earnings Preview
11/10/2025 16:03:42

 neuraxis-receives-fda-clearance-for-its-percutaneous-electrical-nerve-field-stimulation-technology-to-treat-functional-abdominal-pain-and-nausea-associated-with-functional-dyspepsia-in-patients-aged-8-and-older

NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromo...

 neuraxis-q2-eps-022-beats-023-estimate-sales-894086k-miss-967250m-estimate

Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.23) by 4.3...

 earnings-outlook-for-neuraxis
Earnings Outlook For Neuraxis
08/11/2025 18:03:25

 craig-hallum-initiates-coverage-on-neuraxis-with-buy-rating-announces-price-target-of-7

Craig-Hallum analyst Chase Knickerbocker initiates coverage on Neuraxis (AMEX:NRXS) with a Buy rating and announces Price Ta...

 neuraxis-says-proprietary-penfs-technology-officially-incorporated-into-newly-released-clinical-practice-guidelines-issued-by-pediatric-academic-society-for-treatment-of-fap-in-ibs

Practice guidelines published in the Journal of Pediatric Gastroenterology & Nutrition (JPGN) name Percutaneous Electrical ...

 neuraxis-enters-into-definitive-agreements-for-purchase-and-sale-of-15m-shares-at-325shr-in-registered-direct-offering

NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromo...

 neuraxis-receives-fda-510k-clearance-for-ib-stim-for-treatment-of-pediatric-fap-associated-with-functional-dyspepsia-and-fd-related-nausea-symptoms

•   Significantly expands IB-Stim's total addressable market•   Clearance covers patients aged 8–21•   Seamless go-to-marke...

 neuraxis-q4-eps-023-up-from-085-yoy-sales-76116k-up-from-53146k-yoy

Neuraxis (AMEX:NRXS) reported quarterly losses of $(0.23) per share. This is a 72.94 percent increase over losses of $(0.85) pe...

Core News & Articles

NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromo...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION